This is a news story, published by CNBC, that relates primarily to Novo Nordisk news.
For more Novo Nordisk news, you can click here:
more Novo Nordisk newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
weight loss drug industry. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest weight loss drugs news, overweight companies news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Weight Loss ETFCNBC
•73% Informative
Roundhill Investments' GLP-1 & Weight Loss ETF ( OZEM ) pairs leaders Eli Lilly and Novo Nordisk with players developing new treatments for weight loss and diabetes.
CEO Dave Mazza said his firm is capitalizing on explosive growth potential in the industry.
Eli Lilly is up 90% in the past year , while Novo Nisk has gained 68% .
VR Score
82
Informative language
88
Neutral language
31
Article tone
formal
Language
English
Language complexity
42
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links